Academic Contributions and Field Advances of the International Takotsubo Registry: A Comment from Multidimensional Perspectives

Takotsubo syndrome (TTS), also named as stress myocardiopathy, defined by the 2023 European Society of Cardiology (ESC) Position Statement as an acute reversible heart failure syndrome characterized by transient left ventricular dysfunction without obstructive coronary disease, has evolved from a poorly understood condition to a well-defined clinical entity over the past decade.[1] The International Takotsubo (InterTAK) Registry, established in 2011 as the largest multicenter prospective cohort study, has revolutionized the understanding of TTS through its comprehensive data collection and analysis. The InterTAK Registry, which enrolls patients with strict diagnostic criteria including confirmed transient left ventricular dysfunction, exclusion of obstructive coronary disease, and emotional/physical triggers,[2] has prospectively included 3,957 patients from 15 countries worldwide across Europe, Asia, North America, and other regions.[3] Based on insights from 27 core publications derived exclusively from InterTAK Registry data, this commentary systematically synthesizes the InterTAK Registry’s contributions across epidemiology, diagnosis, prognosis, pathophysiology, and clinical management, as well as its transformative role in shaping the field [Figure 1].[2,4-9]Figure 1: Academic contributions and field advances of the International Takotsubo Registry. InterTAK = International Takotsubo; TTS = Takotsubo SyndromeREDEFINING EPIDEMIOLOGY AND CLINICAL HETEROGENEITY: BEYOND STEREOTYPES InterTAK Registry dismantled the traditional view of TTS as a “postmenopausal female disease.” While women still dominate (80%–90%), the registry revealed a rising male prevalence (10%–15%) linked to higher short-term mortality,[3,10] with males accounting for 20% of cases under age 50 years and exhibiting a 2.1-fold increased risk of in-hospital death compared to females.[11] This demographic shift aligns with global trends: the mean age of TTS patients has risen to 71 years in Europe and 73 years in Asia, while the proportion of male patients in low-resource regions remains lower (7%) due to underdiagnosis.[3,12] Notably, ethnic comparisons reveal that Japanese patients are older (mean 75 vs. 67 years in Western cohorts) and more likely to have physical triggers (68% vs. 36%), though ethnicity itself does not independently predict mortality.[12] Meanwhile, this evolving demographic profile coincides with increasing recognition of physical triggers (58% in recent years), such as acute pulmonary disorders (16.7% of physical triggers) and neurological emergencies (e.g., stroke and seizures), which are associated with worse outcomes.[13-15] Notably, COVID-19-related TTS cases highlighted sex-specific mortality risks, with males exhibiting poorer prognoses.[8] The registry further classified TTS into apical (81.7%), midventricular, basal, and focal subtypes.[16] Atypical forms, though less common (18.3%), are prevalent in younger patients and those with neurological comorbidities, underscoring the need for subtype-specific management.[4,7] For instance, midventricular TTS, being increasingly diagnosed (18%–28%), correlates with distinct electrocardiogram (ECG) patterns (e.g., ST-segment depression) and higher arrhythmic risks.[7] DIAGNOSTIC REFINEMENT: FROM INTUITION TO QUANTIFICATION InterTAK Registry’s development of the InterTAK Diagnostic Score[17] marked a paradigm shift. Integrating clinical variables (e.g., female sex and emotional trigger), ECG features (QTc prolongation), and comorbidities (psychiatric/neurological disorders), this tool achieved an area under the curve (AUC) of 0.97 for distinguishing TTS from acute coronary syndrome. Its adoption into ESC guidelines has reduced unnecessary invasive angiography, particularly in cases with high scores (≥ 50).[6,18] For example, a study of female non-ST-segment elevation myocardial infarction patients found that deferring angiography in high-score cases could avoid delays in TTS diagnosis, though caution is needed to avoid missing spontaneous coronary artery dissection.[18] In addition, InterTAK Registry’s identification of “happy heart syndrome” (TTS triggered by positive emotions) expanded the etiological spectrum, revealing similar clinical profiles to classical TTS but with a higher prevalence of midventricular involvement (35% vs. 16.3%).[19] These findings underscore shared neurohormonal pathways between emotional extremes. PROGNOSTIC STRATIFICATION: FROM BIOMARKERS TO MACHINE LEARNING InterTAK Registry redefined risk prediction by validating novel biomarkers and integrating advanced analytics. Elevated cardiac troponin (cTn > 28.8 × upper limit) and persistent C-reactive protein (CRP > 33 mg/L) emerged as independent predictors of mortality.[20,21] Hemodynamic parameters, such as tachycardia (heart rate > 94 bpm) combined with hypotension (systolic blood pressure < 119 mmHg), identified a high-risk subgroup with 3-fold increased mortality.[22] Leveraging machine learning (ML), the InterTAK Registry-ML model[23] outperformed traditional scoring systems, achieving an AUC of 0.89 for in-hospital death prediction. By clustering patients into six phenotypes, it revealed a mortality gradient from 0.5% to 28.8%, emphasizing the heterogeneity of TTS outcomes. Furthermore, texture analysis of cardiac magnetic resonance imaging[9] identified T2-weighted imaging features predictive of 5-year main adverse cardiovascular and cerebrovascular events (MACCE), highlighting the potential of radiomics in prognostication. PATHOPHYSIOLOGICAL INSIGHTS: BRIDGING CLINICAL AND MECHANISTIC RESEARCH InterTAK Registry’s clinical observations catalyzed mechanistic studies. The strong association between TTS and neurological disorders (29.6% in atypical TTS)[7,14] prompted investigations into brain–heart interactions. Induced pluripotent stem cell (iPSC) models demonstrated β1-adrenergic receptor hypersensitivity in TTS cardiomyocytes, characterized by cyclic adenosine monophosphate (cAMP) overactivity and calcium dysregulation.[24] These findings rationalize the efficacy of β-blockers in select cohorts and suggest novel targets (e.g., cAMP pathway inhibitors). The registry also highlighted the role of systemic inflammation, with CRP elevation correlating with myocardial injury severity.[21] This aligns with COVID-19-related TTS studies, where cytokine storms and endothelial dysfunction may exacerbate cardiac stunning.[8] CLINICAL MANAGEMENT: CHALLENGING DOGMAS AND GUIDING PRACTICE InterTAK Registry challenged conventional therapies. Aspirin showed no survival benefit (hazard ratio 1.11 for 5-year MACCE), questioning its routine use.[25] Conversely, cardiac arrest complicating TTS had a 40.3% in-hospital mortality, necessitating tailored resuscitation strategies (e.g., early defibrillation for ventricular arrhythmias).[13] Long-term follow-up revealed a “biphasic risk:” Despite the recovery of left ventricular function, a 5-year MACCE rate of 9.9% underscores the need to recognize TTS as a chronic cardiovascular risk factor.[4,10] This has driven ESC recommendations for long-term monitoring of TTS patients, particularly those with comorbidities such as diabetes or chronic lung disease. ACADEMIC LEGACY AND GLOBAL IMPACT InterTAK Registry’s contributions extend beyond TTS itself, establishing a blueprint for international collaborative research: Data standardization Unified diagnostic criteria (InterTAK diagnostic score) and imaging protocols enabled cross-study comparisons.[4,2] Translational framework Linking clinical data (e.g., triggers and outcomes) with biorepositories and iPSC models accelerated mechanistic discovery.[4,24] Clinical guidelines InterTAK Registry findings underpin ESC and American Heart Association recommendations on TTS management, including risk stratification and therapeutic caution.[4,6] Recent studies, such as the temporal trends analysis[3] and COVID-19 impact assessment,[8] exemplify InterTAK Registry’s adaptability in addressing emerging clinical questions. LIMITATIONS AND FUTURE DIRECTIONS While InterTAK Registry has transformed TTS research, its observational design limits causal inferences. Future priorities include: Mechanistic deep-dive Multiomics profiling (e.g., proteomics, metabolomics) to identify novel biomarkers.[4,9] For instance, InterTAK Registry data could integrate plasma proteomics to validate elevated inflammatory cytokines (e.g., Interleukin-6, tumor necrosis factor-α) linked to catecholamine-driven myocardial injury,[4] while combining CMR texture features with serum metabolomics may reveal associations between myocardial edema heterogeneity and dysregulated energy metabolism (e.g., lactate accumulation).[9] Interventional trials Testing β1-selective blockers, anti-inflammatory agents, and remote ischemic conditioning[26] in high-risk subgroups. A pilot randomized trial is investigating the efficacy of β-blockers in preventing TTS recurrence, with preliminary results suggesting reduced arrhythmic events in high-risk subgroups.[27] Precision prevention Targeting predisposing factors (e.g., neurological disorders) via interdisciplinary care pathways.[15] The InterTAK Neuro-Cardiac Program (NCT01947621), implemented in European centers, integrates neurology and cardiology follow-up for patients with neurological triggers, demonstrating a 20% reduction in 1-year mortality.[15] CONCLUSION The InterTAK Registry has redefined TTS from a “benign mimic” to a complex, heterogeneous syndrome with significant acute and chronic morbidity. By integrating clinical, imaging, and molecular data across diverse populations, the InterTAK Registry has provided a robust evidence base for diagnosis, risk stratification, and mechanism-driven therapy. As the registry evolves, its legacy lies not only in advancing TTS science but also in modeling global collaboration to tackle cardiovascular diseases. Future research is needed to translate these insights into targeted therapies, ultimately improving outcomes for this enigmatic condition.